Attached files
| file | filename |
|---|---|
| EX-31 - OncoCyte Corp | ex31.htm |
| EX-23.1 - OncoCyte Corp | ex23-1.htm |
| EX-21 - OncoCyte Corp | ex21.htm |
| EX-10.44 - OncoCyte Corp | ex10-44.htm |
| EX-4.11 - OncoCyte Corp | ex4-11.htm |
| 10-K - OncoCyte Corp | form10-k.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of OncoCyte Corporation (the “Company”) for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Ronald Andrews, President and Chief Executive Officer, and Mitchell Levine, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1 | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 19, 2021
| /s/ Ronald Andrews | |
| Ronald Andrews | |
| President and Chief Executive Officer | |
| /s/ Mitchell Levine | |
| Mitchell Levine | |
| Chief Financial Officer |